Please ensure Javascript is enabled for purposes of website accessibility

Why Verastem Stock Broke Down Today

By George Budwell – Updated Apr 12, 2019 at 9:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Verastem's new oncology drug isn't setting the world on fire.

What happened

Shares of the small-cap oncology specialist Verastem (VSTM 7.12%) fell by as much as 19.1% on nearly double the average daily volume in early morning trading today. Verastem's shares have since recovered to some degree but remain down by 6.2% as of 1:08 p.m. EDT.  

So what

The oncology company's shares are getting trounced today in response to its disappointing fourth-quarter earnings report released after the bell yesterday. Most critically, Verastem's newly approved leukemia and lymphoma drug Copiktra badly missed consensus revenue estimates for the three-month period.

Man wearing glasses appearing to panic with his hands on top of his head, while sitting in front of a laptop.

Image Source: Getty Images.

Specifically, the company reported that Copiktra sales came in at $1.2 million for the fourth quarter. Wall Street, on the other hand, was expecting a much higher figure of around $2.9 million, according to Factset Consensus.

Check out the latest earnings call transcript for Verastem.

Now what

On the bright side, this latest drop might represent an attractive entry point for bargain hunters for two reasons. First off, Verastem's shares are now being valued at approximately $24 million less than the company's current cash position. That's unusual, even for a pre-revenue biotech, suggesting that Verastem's shares might be near a bottom. Secondly, Copiktra's sales are projected to pick up steam from here on out, perhaps making this beaten-down biotech stock a great pick at these levels. 

The counterpoint to this argument is that Copiktra's commercial launch is already underwater from a momentum standpoint, and it belongs to a class of drugs that simply haven't performed well in the marketplace. As such, investors may want to strongly consider both sides of the argument before taking a flier on this early commercial-stage biotech.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.